Affordable Access

deepdyve-link
Publisher Website

Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate.

Authors
  • Lambrecht, Lawrence J
  • Shekh-Ahmad, Tawfeeq
  • Todd, Wesley M
  • Halvorsen, Mark B
  • Bialer, Meir
Type
Published Article
Journal
Epilepsia
Publication Date
Oct 01, 2011
Volume
52
Issue
10
Pages
1877–1883
Identifiers
DOI: 10.1111/j.1528-1167.2011.03183.x
PMID: 21770925
Source
Medline
License
Unknown

Abstract

Although bioequivalent to Topamax in extent of absorption, USL255 had a slower absorption rate as reflected in its lower C(max) and longer t(max), larger POT and longer t(1/2,eff), and similar R(ac) values to that of Topamax (q12 h). This relative flat plasma profile allows for once-daily dosing with diminished fluctuations in TPM plasma levels. In addition, neither USL255's peak nor extent of plasma exposure of TPM was affected by food.

Report this publication

Statistics

Seen <100 times